Navigation Links
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Date:12/9/2012

those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Contacts:  Sanofi  Media RelationsInvestor RelationsMarisol PeronSebastien MartelTel. : + (33) 1 53 77 45 02 

Tel. : + (33) 1 53 77 45 45E-mail: marisol.peron@sanofi.comE-mail: ir@sanofi.comLauren Musto  Oncology Division Communications Tel: 1 (617) 768-1993; Mobile 1 (781) 572-1147 E-mail: lauren.musto@sanofi.com Carrie Brown U.S. Oncology Division Communicatio
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical ... company engaged primarily in the development of brachytherapy ... applications, today announced that it has filed a ... and Drug Administration ("FDA") for marketing clearance for ... 513(f)(2) of the U.S. Food, Drug and Cosmetic ...
(Date:12/24/2014)... 23, 2014   Assurex Health, a personalized ... healthcare providers for behavioral health and chronic pain ... million in equity financing from new and existing ... President and Chief Executive Officer. The ... of Assurex Health,s GeneSight ®  products.  ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 Savvy executives in pharmaceutical commercial functions ... in today,s volatile healthcare environment. Quantitative and qualitative ... for increased resources, justify costs, or signal necessary ... presidents, directors, and managers tasked with right-sizing investment ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... European Medicines Agency (EMA) has granted orphan designation for ... B. Orphan designation in the European Union provides several ... launch and access to the central authorization procedure. ...
Cached Medicine Technology:Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLC's New Database Search Function 2Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Kathleen Doheny HealthDay Reporter , THURSDAY, Dec. 15 ... that can lead to it, a human papillomavirus (HPV) test ... report. Using it in conjunction with the more traditional ... and prevented more cervical cancers from developing, said study author ...
... a new way to track the progression of multiple sclerosis ... powerful, triple strength MRI to track increasing levels of iron ... levels in MS patients are increasing in grey matter areas ... iron levels in a specific "relay area" were noted in ...
... maker, and the simple quest becomes, well, an ordeal. After doing ... finally make a purchase, only to wonder: "Was this the right ... Reality check: Is this you? If so, new research from ... make a decision that you,ll be happy with. Joyce Ehrlinger, ...
... News) -- Low levels of iron in the blood are ... form in a vein, according to the results of a ... disease. The findings suggest that treating iron deficiency may ... according to the researchers at Imperial College London in England. ...
... used routinely in municipal water distribution systems are a ... from Washington University in St. Louis suggests that the ... worse. The research shows that joining old lead ... galvanic corrosion that can dramatically increase the amount of ...
... Ind. - A patient,s education level is not a ... related to complicated chronic diseases, such as heart failure, ... indicates that some of the better-educated heart failure patients ... well as those who were less educated," said Karen ...
Cached Medicine News:Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 3Health News:Using powerful MRI to track iron levels in brain could be new way to monitor progression of MS 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 3Health News:Low Iron Levels May Increase Blood Clot Risk 2Health News:Lead levels in drinking water spike when copper and lead pipes joined 2Health News:Lead levels in drinking water spike when copper and lead pipes joined 3Health News:Lead levels in drinking water spike when copper and lead pipes joined 4Health News:Lead levels in drinking water spike when copper and lead pipes joined 5Health News:Lead levels in drinking water spike when copper and lead pipes joined 6Health News:Lead levels in drinking water spike when copper and lead pipes joined 7Health News:Heart failure study: Health-literate patients not always adept at managing care 2
... Dehydroepiandrosterone (DHEA) is produced in the adrenal ... gonads [1,2,3]. DHEA serves as a precursor ... relatively weak androgenic activity, estimated at ~10% ... peripubertal children and in adult women, DHEA ...
... testosterone exists as unbound or free testosterone. ... SHBG with high affinity [1], while the ... the albumin-bound and free fractions may be ... action. Measurement of the free or unbound ...
... primary active hormone synthesized within the follicular ... is synthesized via a series of steps ... cells, (ii) iodination of tyrosine residues in ... 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT and DIT), and ...
... protein-3 (IGFBP-3) is the main binding protein for ... component of the ~150 kDa ternary complex. This ... or IGF-II and ALS, allowing IGFBP-3, along with ... The molar concentration of IGFBP-3 in normal serum ...
Medicine Products: